Search

Displaying results 1591 - 1600 of 9667 in total
  1. Drug

    Linvoseltamab

    go.drugbank.com/drugs/DB17447
    ApprovedInvestigational

    [L53353] It received conditional marketing authorization in the European Union in April 2025 for patients with three or more prior lines of therapy, [L53358] and was granted accelerated approval by the … cells with CD3-expressing T cells.

    Categories: Bispecific B Cell Maturation Antigen-directed CD3 T Cell Engager
  2. Drug

    Droxidopa

    go.drugbank.com/drugs/DB06262
    ApprovedInvestigational

    There is a deficit of noradrenaline as well as of dopamine in Parkinson's disease and it has been proposed that this underlies the sudden transient freezing seen usually in advanced disease. … Provided L-DOPS successfully completes clinical trials, it could be approved for the treatment of neurogenic orthostatic hypotension (NOH) as early as 2011.

  3. Drug

    Periciazine

    go.drugbank.com/drugs/DB01608
    Approved

    It is a sedative phenothiazine with weak antipsychotic properties. It also has adrenolytic, anticholinergic, metabolic and endocrine effects and an action on the extrapyramidal system. … It is used as an adjunctive medication in some psychotic patients, for the control of residual prevailing hostility, impulsiveness and aggressiveness.

  4. Drug

    Maralixibat

    go.drugbank.com/drugs/DB16226
    ApprovedInvestigational

    It was granted FDA approval on 29 September 2021. … [A239249] Surgical interventions such as partial external bile diversion and ileal exclusion have also been used as treatments.

  5. Drug

    Cangrelor

    go.drugbank.com/drugs/DB06441
    ApprovedInvestigational

    An advantage Cangrelor provides over oral P2Y12 inhibitors (such as prasugrel, ticagrelor, and clopidogrel) is that it is an active drug not requiring metabolic conversion therefore providing a rapid onset … Cangrelor was approved by the FDA in June 2015 for intravenous application.

  6. Drug

    Lasofoxifene

    go.drugbank.com/drugs/DB06202
    ApprovedInvestigationalWithdrawn

    It was initially developed as Oporia by Pfizer as a treatment for postmenopausal osteoporosis and vaginal atrophy, in which were both rejected for approval by FDA. … It gained approval by European Commission in March 2009.

  7. Drug

    Oxybenzone

    go.drugbank.com/drugs/DB01428
    Approved

    It is used as an ingredient in sunscreen and other cosmetics because it absorbs UV-A ultraviolet rays. … It is a derivative of benzophenone. It forms colorless crystals that are readily soluble in most organic solvents.

    Mixtures: Disney Sun Pals SPF 45 Lotion Nemo, Disney Sun Pals SPF 45 Lotion Mermaid
  8. Drug

    Coal tar

    go.drugbank.com/drugs/DB11082
    Approved

    It has been indicated for local relief of itching, dryness, and irritation caused by psoriasis, seborrhea and eczema. … Coal tars are complex and variable mixtures of phenols, polycyclic aromatic hydrocarbons (PAHs), and heterocyclic compounds.

    Mixtures: PREPARED COAL TAR 5% ET SALICYLIC ACID 2% OINTMENT, Sebcur-TProducts: T/shampoo, Therapeutic T Plus
  9. Drug

    Birch bark extract

    go.drugbank.com/drugs/DB16536
    ApprovedInvestigational

    (white birch), although hybrids of both species are used as well. … Some of the compounds identified in it include betulin, [lupeol], [betulinic acid], oleanolic acid, and erythrodiol.

  10. Drug

    Palonosetron

    go.drugbank.com/drugs/DB00377
    ApprovedInvestigational

    As of 2008, it is the most recent 5-HT3 antagonist to enter clinical use. … It is the most effective of the 5-HT3 antagonists in controlling delayed CINV nausea and vomiting that appear more than 24 hours after the first dose of a course of chemotherapy and is the only drug of

    Synonyms: (3aS)-2-[(3S)-1-azabicyclo[2.2.2]octan-3-yl]-2,3,3a,4,5,6-hexahydro-1H-benzo[de]isoquinolin-1-one